Encequidar mesylate + paclitaxel is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Encequidar mesylate + paclitaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Encequidar mesylate + paclitaxel overview
Oraxol (Paclitaxel and encequidar combination regimen) is under development for the treatment of advanced solid tumors including metastatic breast cancer, esophageal cancer adenocarcinoma of the gastroesophageal junction and soft tissue sarcoma. It is administered orally. HM30181A (encequidar) is a Gl selective third generation P-glycoprotein (P-gp) inhibitor. It is based on Orascovery technology.
It was also under development for the treatment of metastatic transitional (urothelial) tract cancer, non-small cell lung cancer, gastric cancer, cutaneous angiosarcoma,
Hanmi Pharmaceuticals overview
Hanmi Pharmaceuticals, a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, drugs for osteoporosis, liver supplements, and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, and vitamins, among others. The products of Hanmi Pharmaceuticals are used in the treatment of cancer, depression, dementia, dermatology, diabetes, inflammation, cardiovascular conditions, epilepsy, hepatitis, osteoarthritis, gastrointestinal diseases, obesity, osteoporosis, and others. The company operates manufacturing facilities in Hwaseong, Songpa and Pyeongtaek, South Korea. It supplies its products and APIs in various countries in Europe, Asia-Pacific, and the Americas. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.
For a complete picture of Encequidar mesylate + paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.